Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) EBIT Margin (2024 - 2025)

Prelude Therapeutics' EBIT Margin history spans 2 years, with the latest figure at 314.12% for Q3 2025.

  • For Q3 2025, EBIT Margin rose 83174.0% year-over-year to 314.12%; the TTM value through Dec 2025 reached 1608.71%, up 38721.0%, while the annual FY2025 figure was 861.33%, 113458.0% up from the prior year.
  • EBIT Margin for Q3 2025 was 314.12% at Prelude Therapeutics, up from 845.78% in the prior quarter.
  • Across five years, EBIT Margin topped out at 314.12% in Q3 2025 and bottomed at 1145.87% in Q3 2024.